Diabetes mellitus and chronic heart failure

Česká verzia

Authors: Tomáš Bolek; Matej Samoš; Jakub Benko; Jakub Jurica; Martin Jozef Péč; Marek Cingel; Marián Mokáň
Authors place of work: I. interná klinika JLF UK a UNM, Martin
Published in the journal: Forum Diab 2021; 10(3): 173-179
Category:

Summary

Patients with diabetes mellitus (DM) have 2–4 times higher risk to develop heart failure, and a 1 % increasing in glycated hemoglobin (HbA1c) increases the risk of heart failure by 8–36 %. There is evidence that more than 60 % of patients with heart failure have developed insulin resistance. Therefore, DM and heart failure is often linked. There were many studies related to treatment in patients with chronic heart failure with reduced systolic function (HFrEF). Moreover, therapy with sodium-glucose-transporter 2 inhibitors (SGLT2i) has brought a clear benefit in diabetics with HFrEF, but also in patients without DM. However, nowadays, there are a relatively small number of published studies that would evaluate the efficacy of treatment in diabetics with chronic heart failure with moderate reduced (HFmrEF) and preserved left ventricular ejection fraction (HFpEF). In this article, we would like to review the “evidence gap” in the issue of heart failure in patients with DM.

Keywords:

diabetes mellitus – chronic heart failure

Zdroje

1. Abdelaal M, le Roux CW, Docherty NG et al. Morbidity and mortality associated with obesity. Ann Transl Med 2017; 5(7): 161. Dostupné z DOI: <http://dx.doi.org/10.21037/atm.2017.03.107>.

2. Banerjee S, Radak T, Khubchandani J et al. Food Insecurity and Mortality in American Adults: Results From the NHANES-Linked Mortality Study. Health Promot Pract 2021; 22(2): 204–214. Dostupné z DOI:<http://dx.doi.org/10.1177/1524839920945927.

3. Dunlay SM, Givertz MM, Aguilar D et al. Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement From the American Heart Association and the Heart Failure Society of America: This statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update. Circulation 2019; 140(7): e294-e324. Dostupné z DOI: <http://dx.doi.org/10.1161/CIR.0000000000000691>.

4. MacDonald MR, Petrie MC, Varyani F et al. [CHARM Investigators]. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J 2008; 29(11): 1377–1385. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehn153>.

5. Zannad F, McMurray M, Krum H et al. Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms. N Engl J Med 2011; 364(1): 11–21. Dostupné z DOI:<http://dx.doi.org/10.1056/NEJMoa1009492>.

6. Dokken BB. The Pathophysiology of Cardiovascular Disease and Diabetes: Beyond Blood Pressure and Lipids. Diabetes Spectrum 2008; 21(3): 160–165. Dostupné z DOI: <http://dx.doi.org/10.2337/diaspect.21.3.160>.

7. Rubler S, Dlugash J, Yuceoglu YZ et al. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 1972; 30(6): 595–602. Dostupné z DOI:<http://dx.doi.org/10.1016/0002–9149(72)90595–4> .

8. Bulas J, Murin J. Diabetes mellitus a srdcové zlyhávanie. Intern Med 2013; 15(6–7): 220–224.

9. Mokáň M. Galajda P, Martinka E. Diabetes mellitus a vybrané metabolické ochorenia, Vydavatelstvo P+M 2008. ISBN 978–80–969713– 9-8.

10. Ponikowski P, Voors AA, Anker SD et al. [ESC Scientific Document Group]. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016; 37(27): 2129– 2200. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehw128>.

11. Shekelle PG, Rich MW, Morton SC et al. Efficacy of angiotensin- converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol 2003; 41(9):1529–1538. Dostupné z DOI:<http://dx.doi.org/10.1016/s0735–1097(03)00262–6>.

12. MacDonald MR, Petrie MC, Varyani F et al. [CHARM Investigators]. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J 2008; 29(11): 1377–1385. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehn153>.

13. Kristensen SL, Preiss D, Jhund PS et al. [PARADIGM-HF Investigators and Committees]. Risk related to pre-diabetes mellitus and diabetes mellitus in heart failure with reduced ejection fraction: insights from Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial. Circ Heart Fail 2016; 9(1): e002560. Dostupné z DOI:<http://dx.doi.org/10.1161/CIRCHEARTFAILURE.115.002560>.

14. Eschalier R, McMurray JJ, Swedberg K et al. [EMPHASIS-HF Investigators]. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS- HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure). J Am Coll Cardiol 2013; 62(1):1585–1593. Dostupné z DOI:<http://dx.doi.org/10.1016/j.jacc.2013.04.086>.

15. Haas SJ, Vos T, Gilbert RE et al. Are beta-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials. Am Heart J 2003; 146(5): 848–853. Dostupné z DOI: <http://dx.doi.org/10.1016/S0002–8703(03)00403–4>.

16. Komajda M, Tavazzi L, Francq BG et al. [SHIFT Investigators]. Efficacy and safety of ivabradine in patients with chronic systolic heart failure and diabetes: an analysis from the SHIFT trial. Eur J Heart Fail 2015; 17(12): 1294–1301. Dostupné z DOI: <http://dx.doi.org/10.1002/ejhf.347>.

17. Wittenberg SM, Cook JR, Hall WJ et al. [Multicenter Automatic Defibrillator Implantation Trial]. Comparison of efficacy of implanted cardioverter- defibrillator in patients with versus without diabetes melltus. Am J Cardiol 2005; 96(3): 417–419. Dostupné z DOI: <http://dx.doi.org/10.1016/j.amjcard.2005.03.090>.

18. Zinman B, Wanner C, Lachin JM et al. [EMPA-REG OUTCOME Investigators]. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373(22): 2117–2128. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1504720>.

19. Packer M, Anker SD, Butler J et al. [EMPEROR-Reduced Trial Committees and Investigators]. Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload: EMPEROR-Reduced Trial. J Am Coll Cardiol 2021;77(11): 1381–1392. Dostupné z DOI:<http://dx.doi.org/10.1016/j.jacc.2021.01.033>.

20. Neal B, Perkovic V, Mahaffey KW et al. [CANVAS Program Collaborative Group]. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017; 377(7): 644–657. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1611925>.

21. McMurray JJ, Solomon SD, Inzucchi SE et al. [DAPA-HF Trial Committees and Investigators]. Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction – DAPA-HF. N Engl J Med 2019; 381(21): 1995–2008. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1911303>.

22. McDonald M, Virani S, Chan M et al. CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction. Can J Cardiol 2021; 37(4):531– 546. Dostupné z DOI:<http://dx.doi.org/10.1016/j.cjca.2021.01.017> .

23. Margonato D, Mazzetti S, De Maria R et al. Heart Failure With Mid-range or Recovered Ejection Fraction: Differential Determinants of Transition. Cardiac Failure Review; 2020(6): e28. Dostupné z DOI:<http://dx.doi.org/10.15420/cfr.2020.13> .

24. Zhou Q, Li P, Zhao H et al. Heart Failure With Mid-range Ejection Fraction: A Distinctive Subtype or a Transitional Stage? Front Cardiovasc Med 2021; 8: 678121. Dostupné z DOI:<http://dx.doi.org/10.3389/fcvm.2021.678121>.

25. Lund LH, Claggett B, Liu J et al. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. Eur J Heart Fail 2018; 20(8): 1230–1239. Dostupné z DOI: <http://dx.doi.org/10.1002/ejhf.11>.

26. Nie D, Xiong B, Qian J et al. The effect of sacubitril-valsartan in heart failure patients with mid-range and preserved ejection fraction: a meta-analysis. Heart Lung Circ 2020; 30(5): 683–691. Dostupné z DOI:<http://dx.doi.org/10.1016/j.hlc.2020.10.012>.

27. Wachter R, Shah SJ, Cowie MR et al. Angiotensin receptor neprilysin inhibition versus individualized RAAS blockade: design and rationale of the PARALLAX trial. ESC Heart Fail 2020;7(3): 856–864. Dostupné z DOI:<http://dx.doi.org/10.1002/ehf2.12694> .

28. Xiang Y, Shi W, Li Z et al. Efficacy and safety of spironolactone in the heart failure with mid-range ejection fraction and heart failure with preserved ejection fraction: A meta-analysis of randomized clinical trials. Medicine 2019; 98(13): e14967. Dostupné z DOI:<http://dx.doi.org/10.1097/md.0000000000014967> .

29. McDiarmid AK, Swoboda PP, Erhayiem B et al. Myocardial effects of aldosterone antagonism in heart failure with preserved ejection fraction. J Am Heart Assoc 2020: 9(1): e011521. Dostupné z DOI: <http://dx.doi.org/10.1161/JAHA.118.011521>.

30. Yancy CW, Jessup M, Bozkurt B et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American college of cardiology/American heart association task force on clinical practice guidelines and the heart failure society of America. J Am Coll Cardiol 2017; 70(6): 776–803. Dostupné z DOI:<http://dx.doi.org/10.1016/j.jacc.2017.04.025> .

31. Fonarow GC, Stough WG, Abraham WT et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure. J Am Coll Cardiol 2007; 50(8): 768–777. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2007.04.064>.

32. Tsuji K, Sakata Y, Nochioka K et al. Characterization of heart failure patients with mid-range left ventricular ejection fraction-a report from the CHART-2 Study. Eur J Heart Fail 2017; 19(10): 1258–1269. Dostupné z DOI: <http://dx.doi.org/10.1002/ejhf.807>.

33. Cleland JGF, Bunting KV, Flather MD et al. Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. Eur Heart J 2018; 39(1): 26–35. Dostupné z DOI: <http://10.1093/eurheartj/ehx564>.

34. Solomon SD, Zile M, Pieske B et al. [Prospective comparison of ARNI with ARB on Management Of heart failUre with preserved ejectioN fracTion (PARAMOUNT) Investigators]. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet 2012; 380(9851): 1387–1395. Dostupné z DOI:<http://dx.doi.org/10.1016/S0140–6736(12)61227–6>.

35. Solomon SD, McMurray JJ, Anand IS et al. [PARAGON-HF Investigators and Committees]. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. N Engl J Med 2019; 381(17): 1609–1620. Dostupné z DOI:<http://dx.doi.org/10.1056/NEJMoa1908655>.

36. Deswal A, Richardson P, Bozkurt B et al. Results of the Randomized Aldosterone Antagonism in Heart Failure with Preserved Ejection Fraction trial (RAAM-PEF). J Card Fail 2011; 17(8): 634–642. Dostupné z DOI: <http://dx.doi.org/10.1016/j.cardfail.2011.04.007>.

37. Pitt B, Pfeffer MA, Assmann SF et al. [TOPCAT Investigators]. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 2014; 370(15): 1383–1392. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1313731>.

38. Yancy CW, Jessup M, Bozkurt B et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol 2017; 70(6): 776– 803. Dostupné z DOI:<http://dx.doi.org/10.1016/j.jacc.2017.04.025>.

39. Brandt-Jacobsen NH, Lav Madsen P, Johansen ML et al. Mineralocorticoid Receptor Antagonist Improves Cardiac Structure in Type 2 Diabetes: Data From the MIRAD Trial. JACC Heart Fail 2021; 9(9): 550– 558. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jchf.2021.02.016>.

40. van Veldhuisen DJ, Cohen-Solal A, Böhm M et al. [SENIORS Investigators]. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). J Am Coll Cardiol 2009; 53(23): 2150–2158. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2009.02.046>.

41. Yamamoto K, Origasa H, Hori M. [J-DHF Investigators]. Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF). Eur J Heart Fail 2013; 15(1): 110–118. Dostupné z DOI:<http://dx.doi.org/10.1093/eurjhf/hfs141> .

42. Komajda M, Isnard R, Cohen-Solal A et al. [prEserveD left ventricular ejectIon fraction chronic heart Failure wit ivabradine studY (EDIFY) Investigators]. Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trial. Eur J Heart Fail 2017; 19(11): 1495–1503. Dostupné z DOI:<http://dx.doi.org/10.1002/ejhf.876> .

43. Anker SD, Butler J, Filippatos GS et al. [EMPEROR-Preserved Trial Committees and Investigators]. Evaluation of the effects of sodium- glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial. Eur J Heart Fail 2019; 21(10): 1279–1287. Dostupné z DOI:<http://dx.doi.org/10.1002/ejhf.1596>.

44. Solomon SD, de Boer RA, DeMets D et al. Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial. Eur J Heart Fail 2021; 23(7): 1217–1225. Dostupné z DOI:<http://dx.doi.org/10.1002/ejhf.2249>.